Search PubMed⌕ Search

Biomedical subjects

N Pfeiffer

Publications and source records attributed to N Pfeiffer.

At least 109 records · Page 6Linked to original sources
PubMed1992

Misdirected regeneration of abducens nerve neurons into the parasympathetic pupillary pathway.

A 16-year-old girl suffered a severe head trauma with paralyses of the right oculomotor, trochlear, and abducens nerves. Three years later, only the abducens nerve had recovered. The pupil did not react to light or near. However, the diameter of the pupil correlated with horizontal gaze: with the gaze to the left, the diameter of the pupil was 8 mm, with the gaze straight ahead, 6 mm, and with the gaze to the right, 4 mm. With saccades to the right, the pupil started to constrict immediately and reached its smallest diameter after about 2 s. We conclude that the constriction of the pupil was due to misdirected regeneration of abducens nerve neurons into the parasympathetic pathway of the oculomotor nerve.

Abducens Nerve↗
PubMed1992

Improved suture for fornix-based conjunctival flap in filtering surgery.

Major problems in the early postoperative phase in filtering surgery are hypotony, flattening of the anterior chamber and choroidal detachment. We describe a new suture technique for the closure of the conjunctiva in goniotrephination with a fornix-based conjunctival flap which is helpful in reducing these complications. After dissecting the conjunctiva from the limbus, a shallow groove is cut directly behind the former conjunctival insertion. At the end of the operation the conjunctiva is sutured into this groove using a running 10.0 nylon suture in a meander-like fashion. A very tight wound closure results. We used this technique in 104 consecutive goniotrephinations. We found a low incidence of only mild external fistulation, hypotony, flattening of the anterior chamber and choroidal detachment. Astigmatism induced by the operation was -1.2 +/- 1.2 D, usually with the rule.

Aged↗
PubMed1992

Sezolamide: additivity to timolol twice daily.

Sezolamide, a potent topical carbonic anhydrase inhibitor previously known as MK-417, was studied to determine its ocular hypotensive activity in patients with elevated intraocular pressure while on continuing therapy with topical timolol. This was a three-centre, double-masked, randomised, placebo-controlled, parallel study in 36 patients with bilateral primary open angle glaucoma or ocular hypertension on therapy receiving 0.5% timolol twice daily, with a morning intraocular pressure greater than or equal to 22 mmHg in both eyes 2-4 hours following an 8 a.m. dose of timolol. Sezolamide 1.8% or placebo twice daily was added to treatment with timolol on the evening of day 1 and continued for 2 weeks. Twelve-hour diurnal curves were performed before the study on day 1 (timolol alone) and on day 15. Intraocular pressure measurements were also taken on days 2 and 8 at 8 a.m. and 9 a.m. Patients who received timolol and sezolamide showed additional intraocular pressure reductions from day 1 (timolol alone) of 8.0 to 15.5%, which were significant at all times. At hours 1, 2, 4 and 8 the reductions in intraocular pressure observed in the group receiving sezolamide and timolol were significantly greater than those in the group receiving timolol and placebo.

Aged↗
PubMed1992

The pattern-electroretinogram in glaucoma and ocular hypertension. A cross-sectional and longitudinal study.

The pattern electroretinogram (PERG) is an indicator of retinal ganglion cell function. We studied the PERG in 65 normal eyes, in 52 eyes in early stages of glaucoma, and in 28 ocular hypertensive (OHT) eyes. The PERG was recorded using steady-state high contrast (98%) counterphasing checkerboard patterns at check sizes of 0.8 degrees and 15 degrees at 16 reversals/s and 98% contrast. Stimulation area was 27 degrees x 30 degrees. When compared to normals, in glaucoma eyes PERG amplitudes are reduced to 56 +/- 3.6%, (P < 0.0001) for 0.8 degrees and to 79 +/- 4.0% (P < 0.001) for 15 degrees check sizes. Preferential reduction for the small check size allows classification of patients on an individual basis: using discriminant analysis, normal and glaucoma eyes were classified with a sensitivity of 82.7% and a specificity of 90.8%. Nineteen of 28 OHT eyes were classified as pathological. Eyes with OHT were followed up to test whether the PERG can be used to predict visual field damage. At the repeat visit 5 to 35 months later (mean follow-up 20.2 +/- 8.2 months), in eyes with normal PERGs the average loss in mean sensitivity was -0.61 +/- 0.5 dB, while in eyes with pathological PERGs it was -2.6 +/- 0.7 dB (P = 0.05). Findings suggest that the PERG can be used to discriminate between OHT patients who will develop visual field loss and those who will not. Thus, the PERG may be a test of visual function helpful to decide which OHT patients require treatment before visual field deterioration and optic nerve damage have begun.

Adult↗
PubMed1991

Comparative tolerability of topical carbonic anhydrase inhibitor MK-927 and its S-enantiomer MK-417.

A single-dose, randomised, double-masked, placebo-controlled, five-period cross-over comparative ocular tolerance study was undertaken with the topical carbonic anhydrase inhibitor (CAI) MK-927 (1% and 2% concentrations) and its S-enantiomer MK-417 (1% and 1.8% concentrations) in 20 healthy, normal volunteers. Subjects received one drop of placebo (common vehicle) or CAI in each eye on five different days that were separated by washout intervals of 1 week. The incidence of burning increased significantly after treatment with 2% MK-927 (P less than 0.01) and 1.8% MK-417 (P less than 0.05) as compared with placebo. The mean duration of burning following placebo was 16.8 s, somewhat less than that following CAI application (23-37.1 s). The duration of tearing following CAI treatment was also significantly prolonged (P less than 0.05). Pupil size was not changed by CAIs. No other side effects were observed. At 3 h after instillation, intraocular pressure (IOP) was found to be decreased following all four CAI treatments, significantly so with 1% and 1.8% MK-417. The reasonable single-dose tolerability of MK-927 and MK-417 in this sensitive normal-volunteer model supports their potential as topical glaucoma medications. This study suggests that MK-417 may possess greater IOP-lowering activity than MK-927 in man.

Administration, Topical↗
PubMed1991

[Pattern ERG in ocular hypertension and glaucoma. Effect of pattern size, contrast and retinal eccentricity].

We have previously shown that check-size-specific changes of the Pattern-Electroretinogram (PERG) can be used to detect early glaucoma. This time we conducted a study to determine whether different check sizes, contrasts and eccentricities can improve the diagnostic yield. We examined 15 normal eyes (15 subjects), 32 eyes (24 patients) in stage I or II glaucoma and 36 eyes (25 patients) with ocular hypertension (OHT). Visual acuity was always better than 0.8. The stimuli were checkerboards, phase-reversing at 16 rev/s. The check sizes were 0.8 degrees or 15 degrees with contrast at 60% or 98%. The stimulation area was either "full-field" (27 degrees x 30 degrees), "central" (less than or equal to 7 degrees) or "paracentral" (greater than 7 degrees). In the glaucoma group, all PERG amplitudes were significantly reduced compared to normals: maximally for stimuli of 0.8 degrees, 98% contrast, full-field to 51% +/- 18%, and least for stimuli of 15 degrees, 98% contrast, central (to 70% +/- 20%). Under paracentral stimulation, the amplitude was reduced to 55% and in the central condition to 64%. The single-most-sensitive stimulus to separate normal and glaucoma patients was 0.8 degrees, 60% contrast and full-field, as the variance was low for this condition. Only 4 patients (8.5%) were incorrectly classified using these parameters; when 8 different stimuli were entered into the discriminant analysis, the rate was marginally reduced to 3 patients (6.4%). Seventy-five percent of the OHT eyes were classified as pathological. These results confirm previous findings that in early glaucoma, PERG amplitudes are more reduced using check sizes of 0.8 degrees compared to 15 degrees.(ABSTRACT TRUNCATED AT 250 WORDS)

Electroretinography↗
PubMed1991

[Additive effect of timolol and the local carbonic anhydrase inhibitor MK-417 (sezolamide)].

MK-417 (sezolamide) is a topically active carbonic anhydrase inhibitor. The effect of additional treatment with sezolamide 1.8% twice daily to patient already receiving timolol 0.5% twice daily was investigated. For this purpose, 12-h diurnal curves were used in a double-masked, randomized, placebo-controlled, parallel study in 36 patients with bilateral primary open angle glaucoma or ocular hypertension who during beta blocker therapy had intraocular pressures (IOP) greater than or equal to 22 mmHg. For 15 days patients received sezolamide or placebo 10 min after 0.5% timolol given at 8 a.m. and 8 p.m. On treatment day 15, this addition of sezolamide twice daily induced a further mean decrease in IOP of approximately 4 mm Hg (about 15%) at 1, 2 and 4 h and of approximately 2-3 mm Hg at 0, 6, 8, 10 and 12 h after drug administration, thus demonstrating a partial additive effect of sezolamide and timolol. Thus, sezolamide may be a useful addition to the treatment of glaucoma in patients not adequately controlled by beta blocker therapy.

Aged↗
PubMed1990

A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients.

MK-927 is a novel topical carbonic anhydrase inhibitor (CAI). We present the first single-dose clinical trial of MK-927 in 24 patients with bilateral primary open-angle glaucoma or ocular hypertension. This investigation was conducted as a two-centre, double-masked, randomised, placebo controlled study. Patients received one drop of 2% MK-927 in one eye and placebo in the other eye. Modified diurnal intraocular pressure (IOP) curves were performed before the study and on one treatment day. A single dose of 2% MK-927 induced a peak mean IOP decrease of 10.5 mmHg at 4.5 hours postdose. With compensation for diurnal variation, as determined by the prestudy diurnal pressure curve, the net peak mean reduction of IOP caused by MK-927 was 7.5 mmHg versus a corresponding net change of 1.4 mmHg in the contralateral placebo treated eye. Thus a single dose of MK-927 gave a clinically significant IOP reduction in patients.

Carbonic Anhydrase Inhibitors↗